Inhibitors of human EZH2 and methods of use thereof
View Patent ↗The invention relates to determining the presence of an EZH2 gene mutation in a sample from a subject and inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono-through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject.
1. A method comprising:
(i) providing a nucleic acid sample from a biological sample obtained from a subject;
(ii) contacting the nucleic acid sample with at least one primer that specifically hybridizes to a portion of SEQ ID NO: 7 having a mutation at the nucleotides encoding position Tyr641 (Y641) of Enhancer of Zeste homolog 2 (EZH2) of SEQ ID NO: 1, wherein the mutation increases EZH2 trimethylation of Lys27 of histone H3 (H3-K27);
(iii) detecting the presence of the mutation at the nucleotides encoding Y641 in the nucleic acid sample by detecting the presence of a nucleic acid encoding the mutation at Y641;
(iv) identifying the subject as a candidate for treatment; and
(v) administering a therapeutically effective amount of an EZH2 inhibitor to the subject identified in step (iv), wherein the EZH2 inhibitor inhibits the conversion of H3-K27 to trimethylated H3-K27.
2. The method of claim 1 , wherein the subject has a cancer selected from leukemia, melanoma, and lymphoma, or is at risk of developing a cancer selected from leukemia, melanoma, and lymphoma.
3. The method of claim 2 , wherein the lymphoma is selected from the group consisting of Non-Hodgkin's lymphoma, follicular lymphoma and diffuse large B-cell lymphoma (DLBCL) of germinal center B cell-like (GCB) subtype.
4. The method of claim 1 , where in the EZH2 inhibitor is a small molecule.
5. A method comprising:
(i) providing a nucleic acid sample from a biological sample obtained from a subject;
(ii) contacting the nucleic acid sample with at least one primer that specifically hybridizes to a portion of SEQ ID NO: 7 having a mutation at the nucleotides encoding position Y641 of EZH2 of SEQ ID NO: 1, wherein the mutation increases EZH2 trimethylation of Lys27 of histone H3 (H3-K27);
(iii) detecting the presence of the mutation at the nucleotides encoding Y641 in the nucleic acid sample by detecting the presence of a nucleic acid encoding the mutation at Y641;
(iv) identifying the subject as a candidate for treatment;
(v) selecting a therapy that includes the administration of a therapeutically effective amount of an EZH2 inhibitor to the subject identified in step (iv), wherein the EZH2 inhibitor inhibits the conversion of H3-K27 to trimethylated H3-K27; and
(vi) administering the therapeutically effective amount of the EZH2 inhibitor that inhibits the conversion of H3-K27 to trimethylated H3-K27 to the subject.
6. The method of claim 5 , wherein the subject has a cancer selected from leukemia, melanoma, and lymphoma, or is at risk of developing a cancer selected from leukemia, melanoma, and lymphoma.
7. The method of claim 6 , wherein the lymphoma is selected from the group consisting of Non-Hodgkin's lymphoma, follicular lymphoma and diffuse large B-cell lymphoma (DLBCL) of germinal center B cell-like (GCB) subtype.
8. The method of claim 5 , wherein the EZH2 inhibitor is a small molecule.
9. A method comprising,
(i) providing a nucleic acid sample from a biological sample obtained from a subject;
(ii) contacting the nucleic acid sample with at least one primer that specifically hybridizes to a portion of SEQ ID NO: 7 having a mutation at the nucleotides encoding position Y641 of EZH2 of SEQ ID NO: 1, wherein the mutation increases EZH2 trimethylation of Lys27 of histone H3 (H3-K27);
(iii) amplifying the portion of SEQ ID NO:7 having a mutation at the nucleotides encoding position Y641;
(iv) detecting the mutation at the nucleotides encoding position Y641 by detecting the presence of the amplified nucleic acid;
(v) selecting a therapy that includes the administration of a therapeutically effective amount of an EZH2 inhibitor to the subject when the amplified nucleic acid is detected in step (iv), wherein the EZH2 inhibitor inhibits the conversion of H3-K27 to trimethylated H3-K27; and
(vi) administering the therapeutically effective amount of the EZH2 inhibitor that inhibits the conversion of H3-K27 to trimethylated H3-K27 to the subject.
10. The method of claim 1 wherein the mutation at the nucleotides encoding position Y641 is selected from the group consisting of Y641F, Y641H, Y641N and Y641S.
11. The method of claim 5 , wherein the mutation at the nucleotides encoding position Y641 is selected from the group consisting of Y641F, Y641H, Y641N and Y641S.
12. The method of claim 9 , wherein the mutation at the nucleotides encoding position Y641 is selected from the group consisting of Y641F, Y641H, Y641N and Y641S.